How would you approach treatment of a patient with metastatic NSCLC with PD-L1>1% and HER2-mutation?  

Does this change for PDL1 1-49% vs >50%? Will you be more likely to employ other checkpoint inhibitors before use of HER2 targeting therapy? Or start with targeted therapy and reserve checkpoint inhibitors for later lines?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice